Long-Term Survival After Chemoradiotherapy for Renal Pelvis Cancer

Q4 Medicine
Yukinobu Shimada, Hiroyuki Kitano, Shunsuke Miyamoto, Kohei Kobatake, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Yutaka Hirokawa, Nobuyuki Hinata
{"title":"Long-Term Survival After Chemoradiotherapy for Renal Pelvis Cancer","authors":"Yukinobu Shimada,&nbsp;Hiroyuki Kitano,&nbsp;Shunsuke Miyamoto,&nbsp;Kohei Kobatake,&nbsp;Keisuke Goto,&nbsp;Akihiro Goriki,&nbsp;Keisuke Hieda,&nbsp;Yutaka Hirokawa,&nbsp;Nobuyuki Hinata","doi":"10.1002/iju5.70052","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Despite the recent increase in applicable chemotherapy regimens for renal pelvic and ureteral cancer, patients with metastases still exhibit a poor prognosis. Here, we report a patient with renal pelvic cancer for whom long-term survival was achieved using chemoradiotherapy.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>A 62-year-old woman diagnosed with renal pelvic cancer showed indications of a right renal pelvic tumor with para-aortic and iliac lymph node metastasis on computed tomography. Radiotherapy doses of 55 and 66 Gy were administered to the primary lesion, para-aortic lymph node, and right iliac lymph nodes after chemotherapy with gemcitabine, cisplatin, and docetaxel. Five years after treatment, no recurrence was observed.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Chemoradiotherapy is a potential therapeutic option for patients with renal pelvic carcinoma in whom surgical intervention is challenging owing to complications or older age.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"8 5","pages":"441-444"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.70052","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.70052","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Despite the recent increase in applicable chemotherapy regimens for renal pelvic and ureteral cancer, patients with metastases still exhibit a poor prognosis. Here, we report a patient with renal pelvic cancer for whom long-term survival was achieved using chemoradiotherapy.

Case Presentation

A 62-year-old woman diagnosed with renal pelvic cancer showed indications of a right renal pelvic tumor with para-aortic and iliac lymph node metastasis on computed tomography. Radiotherapy doses of 55 and 66 Gy were administered to the primary lesion, para-aortic lymph node, and right iliac lymph nodes after chemotherapy with gemcitabine, cisplatin, and docetaxel. Five years after treatment, no recurrence was observed.

Conclusion

Chemoradiotherapy is a potential therapeutic option for patients with renal pelvic carcinoma in whom surgical intervention is challenging owing to complications or older age.

Abstract Image

肾盂癌放化疗后的长期生存率
尽管近年来适用于肾盆腔癌和输尿管癌的化疗方案有所增加,但转移患者的预后仍然很差。在这里,我们报告了一位通过放化疗获得长期生存的肾盂癌患者。病例介绍一名62岁女性,诊断为肾盂癌,在计算机断层扫描上显示右侧肾盆腔肿瘤伴主动脉旁淋巴结和髂淋巴结转移。在吉西他滨、顺铂和多西他赛化疗后,对原发病灶、主动脉旁淋巴结和右髂淋巴结给予55和66 Gy的放疗剂量。治疗后5年未见复发。结论放化疗是肾盆腔癌因并发症或高龄难以手术治疗的潜在治疗选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
IJU Case Reports
IJU Case Reports Medicine-Urology
CiteScore
0.60
自引率
0.00%
发文量
147
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信